---
title: "Three-year data support drug-eluting resorbable scaffold as “durable, effective endovascular treatment option” for CLTI"
date: "2025-11-03T22:49:29.000Z"
publishedDate: "3 novembre 2025"
summary: "Three-year data from the LIFE-BTK randomised controlled trial, presented today at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA), demonstrate the prolonged efficacy and safety of the Esprit BTK drug-eluting resorbable scaffold (DRS; Abbott) in chronic limb-threatening ischaemia (CLTI). Sahil Parikh (Columbia University Irving Medical Center, New York, USA) reported that, at three [&#8230;] The post Three-year data support drug-eluting resorbable scaffold as “durable, effective endovascular treatment option” for CLTI appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/three-year-data-support-drug-eluting-resorbable-scaffold-as-durable-effective-endovascular-treatment-option-for-clti/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2025-11-03-three-year-data-support-drug-eluting-resorbable-scaffold-as-durable-effective-endovascular-treatment-option-for-clti"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2025/11/Parikh-web.png"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/three-year-data-support-drug-eluting-resorbable-scaffold-as-durable-effective-endovascular-treatment-option-for-clti/"
---

![Three-year data support drug-eluting resorbable scaffold as “durable, effective endovascular treatment option” for CLTI](https://vascularnews.com/wp-content/uploads/sites/7/2025/11/Parikh-web.png)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/three-year-data-support-drug-eluting-resorbable-scaffold-as-durable-effective-endovascular-treatment-option-for-clti/*

## L’essentiel

Three-year data from the LIFE-BTK randomised controlled trial, presented today at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA), demonstrate the prolonged efficacy and safety of the Esprit BTK drug-eluting resorbable scaffold (DRS; Abbott) in chronic limb-threatening ischaemia (CLTI). Sahil Parikh (Columbia University Irving Medical Center, New York, USA) reported that, at three [&#8230;] The post Three-year data support drug-eluting resorbable scaffold as “durable, effective endovascular treatment option” for CLTI appeared first on Vascular News .

## Lien source

https://vascularnews.com/three-year-data-support-drug-eluting-resorbable-scaffold-as-durable-effective-endovascular-treatment-option-for-clti/
